| abstract |
The invention relates to the field of cancer, preferably to nasopharyngeal carcinoma (NPC), and in particular to new products, compositions, plasmid vector and methods for cancer therapy. n The present invention relates in particular to products containing: n(iii) at least one antagonist of c-IAP2 (cellular inhibitor of apoptosis protein 2), and n(iv) at least one agonist of TLR3 (Toll Like Receptor 3), n nas a combined preparation for simultaneous, separate, or sequential use for treating a cancer expressing c-IAP2, preferably nasopharyngeal carcinoma (NPC), in a subject. |